The rarest and most dangerous type of biliary tract malignancy is Gall Bladder cancer (GBC). Sadly, only a small percentage of cancer patients can successfully undergo surgical resection, the current standard of care; as a result, the high mortality rate has remained constant for years. Due to the development of cutting- edge technological tools (such as next-generation sequencing, transcriptomics, and proteomics), a number of therapeutic strategies—including targeted therapy, immunotherapy, and nanoparticle-based delivery systems—have been vigorously innovated in order to significantly avoid the stagnant scenario. In this review, we largely concentrate on targeted therapies that can effectively block particular critical molecules that control abnormal signalling cascades in GBC. Updated global clinical trials for GBC focused therapy may provide significant benefit for new pathological and therapeutic insights.
